Baidu
map

JAMA:利拉利汀不会增加II型糖尿病患者的心血管及肾脏疾病风险

2019-01-09 zhangfan MedSci原创

研究认为,利拉利汀不会增加II型糖尿病患者的心血管及肾脏疾病风险。

II型糖尿病患者血管疾病(CV)风险增加,先前有证据表明长期使用DPP-4抑制剂增加患者血管及肾疾病风险。近日研究人员考察了选择性DDP-4抑制剂利拉利汀对II型糖尿病伴高CV及肾疾病风险人群心血管及肾脏功能的影响。

II型糖尿病患者参与研究,其血红蛋白A1C 6.5-10.0%,具有血管疾病史、尿白蛋白肌酐比值[UACR]>200 mg/g)、EGFR降低或存在蛋白尿。患者随机在常规治疗基础上,接受5mg每日的利拉利汀(n=3494)或安慰剂(n=3485)。研究的主要终点为CV死亡、非致死性心肌梗死或非致死性卒中

患者平均年龄65.9岁,平均eGFR为54.6 mL/min/1.73 m2; 80.1% 患者UACR >30 mg/g。在2.2年的随访期间,治疗组434人出现终点事件,安慰剂组420人(12.4% vs 12.1%,绝对差异0.13,HR=1.02)。治疗组327人以及安慰剂组306人出现肾疾病事件(9.4% vs 8.8%,绝对差异0.22,HR=1.04。组间不良事件率相近,大部分为血糖,治疗组9例(0.3%)以及安慰剂组5例(0.1%)患者发生急性胰腺炎。

研究认为,利拉利汀不会增加II型糖尿病患者的心血管及肾脏疾病风险。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=359293, encodeId=95333592931e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Jan 26 18:32:44 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429709, encodeId=a5ca1429e0906, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Fri Jan 11 05:08:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473158, encodeId=2bba14e31587b, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Jan 11 05:08:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474684, encodeId=acb614e46849f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jan 11 05:08:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042190, encodeId=61101042190e4, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 09 17:08:00 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
    2019-01-26 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=359293, encodeId=95333592931e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Jan 26 18:32:44 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429709, encodeId=a5ca1429e0906, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Fri Jan 11 05:08:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473158, encodeId=2bba14e31587b, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Jan 11 05:08:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474684, encodeId=acb614e46849f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jan 11 05:08:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042190, encodeId=61101042190e4, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 09 17:08:00 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=359293, encodeId=95333592931e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Jan 26 18:32:44 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429709, encodeId=a5ca1429e0906, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Fri Jan 11 05:08:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473158, encodeId=2bba14e31587b, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Jan 11 05:08:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474684, encodeId=acb614e46849f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jan 11 05:08:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042190, encodeId=61101042190e4, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 09 17:08:00 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=359293, encodeId=95333592931e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Jan 26 18:32:44 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429709, encodeId=a5ca1429e0906, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Fri Jan 11 05:08:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473158, encodeId=2bba14e31587b, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Jan 11 05:08:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474684, encodeId=acb614e46849f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jan 11 05:08:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042190, encodeId=61101042190e4, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 09 17:08:00 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=359293, encodeId=95333592931e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Jan 26 18:32:44 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429709, encodeId=a5ca1429e0906, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Fri Jan 11 05:08:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473158, encodeId=2bba14e31587b, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Jan 11 05:08:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474684, encodeId=acb614e46849f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Jan 11 05:08:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042190, encodeId=61101042190e4, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 09 17:08:00 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
    2019-01-09 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Cell Metab:药物“鸡尾酒”:糖尿病研究迈出重要一步

近日,科学家在寻找恢复人体自造胰岛素能力的糖尿病治疗方法中,迈出了关键一步。他们创造出两种药物的“鸡尾酒”可以诱导产生胰岛素的细胞快速再生,其再生速度足以用于人体治疗。这项由美国纽约西奈山伊坎医学院的研究人员完成的研究揭示两种药物的新组合如何使成年人β细胞以每天5%-8%的速率进行复制。该研究近日已发表在《Cell Metabolism》上。研究通讯作者、西奈山糖尿病、肥胖和新陈代谢研究所的负责人

JAMA:“苹果型身材”易患糖尿病、心脏病?是基因突变在作怪!

“苹果型身材”与患糖尿病和心脏病的风险增加有关——这是科学家们很早之前就发现的一个现象

糖尿病合并痛风患者饮食需注意!

痛风是由于嘌呤代谢紊乱所引起的一组代谢性疾病, 包括高尿酸血症、 反复发作的急性关节炎、 痛风石沉积、 痛风性慢性关节炎以及痛风性肾病等。痛风饮食营养治疗总原则 : “三低一高” , 即低嘌呤饮食、 减轻体重、 低盐低脂膳食和大量饮水。

Cell Metab:他汀药物会减少褐色脂肪组织

近日,苏黎世联邦理工学院(ETH)的研究人员发现,他汀类药物(最常见的降血脂药物)会减少帮助我们抵抗糖尿病的褐色脂肪,还会阻止白色脂肪褐化。但研究人员表示,我们没有必要将这种药物妖魔化。

联康集团口服抗糖尿病药阿卡波糖片获国家药品监督管理局正式受理

2019年1月4日,具备研发、生产及销售的一体化生物制药商 -- 联康生物科技集团有限公司(“联康集团”或“本公司”,连同其附属公司统称“本集团”,股份代号:690)之全资附属公司北京博康健基因科技有限公司与北京百奥药业有限公司共同开发的阿卡波糖片生物等效性研究(“BE研究”)临床数据已获国家药品监督管理局正式受理,受理号为CYHS1900008国及CYHS1900007国,分别对应本次提交受理的

Molecular Nutrition & Food Research:鸡蛋竟能降低糖尿病风险!

在西方国家有一句谚语:An apple a day keeps the doctor away(每日一苹果,医生远离我)。而最近芬兰科学家的研究却表明:每日一鸡蛋,糖尿病远离我。 东芬兰大学进行的一项研究表明,每天摄入一个鸡蛋似乎与血液代谢物特征相关,这与2型糖尿病风险较低有关。该研究结果发表在知名期刊《Molecular Nutrition and Food Research》上,基于

Baidu
map
Baidu
map
Baidu
map